---

---

entities : Regeneron pharmaceuticals, inc.    symbols : SNY   

save search

---

Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Published: 2024-04-07 (Crawled : 20:20) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K |

Health Technology

| 0.01% | O: 2.24% H: 0.0% C: -0.8%
SNY | News | $46.32 2.05% 2.01% 3.3M |

Health Technology

| -1.33% | O: 0.84% H: 0.0% C: 0.0%
REGN | $896.27 0.26% 0.25% 500K |

Health Technology

| -4.4% | O: 0.11% H: 0.32% C: -0.07%
response

---

Regeneron Provides Update on Biologics License Application for Odronextamab
Published: 2024-03-25 (Crawled : 11:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K |

Health Technology

| -1.09% | O: -100.0% H: NaN% C: Infinity%
SNY | News | $46.32 2.05% 2.01% 3.3M |

Health Technology

| -3.68% | O: 0.42% H: 0.0% C: 0.0%
REGN | $896.27 0.26% 0.25% 500K |

Health Technology

| -7.28% | O: -1.37% H: 1.15% C: 0.74%
license update application

---

Monoclonal Antibody (mABs) Therapeutics Market Worth $497.5 billion | MarketsandMarkets™
Published: 2024-03-15 (Crawled : 14:30) - prnewswire.com
TAK | News | $13.24 0.61% 0.0% 1.3M |

Health Technology

| -7.67% | O: 0.21% H: 0.97% C: 0.7%
NVS | $94.36 1.93% 0.0% 2.3M |

Health Technology

| -3.84% | O: 0.05% H: 0.14% C: -0.93%
JNJ | News | $147.91 1.49% -0.03% 9.6M |

Health Technology

| -8.01% | O: -1.58% H: 0.0% C: 0.0%
LLY | News | $726.31 -2.63% -0.04% 3.5M |

Health Technology

| -4.52% | O: -0.7% H: 0.73% C: -0.16%
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| -7.71% | O: -0.07% H: 0.0% C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M |

Health Technology

| -4.4% | O: -0.02% H: 0.0% C: 0.0%
REGN | $896.27 0.26% 0.25% 500K |

Health Technology

| -6.49% | O: -0.27% H: 1.26% C: 0.84%
AMGN | $269.03 2.39% 2.33% 3.4M |

Health Technology

| -0.96% | O: 0.2% H: 1.14% C: -1.18%
antibody therapeutics market

---

Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol
Published: 2024-03-11 (Crawled : 11:00) - globenewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M |

Health Technology

| -3.66% | O: 0.57% H: 0.0% C: 0.0%
REGN | $896.27 0.26% 0.25% 500K |

Health Technology

| -7.43% | O: 0.23% H: 0.9% C: -0.68%
praluent fda children genetic cholesterol approval treat injection

---

EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet
Published: 2024-03-08 (Crawled : 12:00) - globenewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M |

Health Technology

| -3.74% | O: -0.08% H: 0.0% C: 0.0%
REGN | $896.27 0.26% 0.25% 500K |

Health Technology

| -7.86% | O: 0.0% H: 0.27% C: -0.46%
eylea lancet macular injection diabetic

---

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation
Published: 2024-02-23 (Crawled : 06:00) - globenewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M |

Health Technology

| -3.37% | O: 0.97% H: 0.0% C: 0.0%
REGN | $896.27 0.26% 0.25% 500K |

Health Technology

| -7.05% | O: 1.05% H: 1.09% C: 0.64%
dupixent fda review treatment copd

---

Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation
Published: 2024-02-23 (Crawled : 06:00) - globenewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M |

Health Technology

| -3.37% | O: 0.97% H: 0.0% C: 0.0%
REGN | $896.27 0.26% 0.25% 500K |

Health Technology

| -7.05% | O: 1.05% H: 1.09% C: 0.64%
dupixent fda review treatment copd

---

Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review
Published: 2024-02-21 (Crawled : 12:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K |

Health Technology

| -1.49% | O: 1.7% H: 0.0% C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M |

Health Technology

| -2.32% | O: -0.57% H: 0.0% C: 0.0%
REGN | $896.27 0.26% 0.25% 500K |

Health Technology

| -5.29% | O: 0.54% H: 0.63% C: 0.09%
fda review treatment

---

Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)
Published: 2024-02-16 (Crawled : 06:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K |

Health Technology

| 0.42% | O: 1.66% H: 0.0% C: -1.59%
SNY | News | $46.32 2.05% 2.01% 3.3M |

Health Technology

| -0.45% | O: -0.6% H: 0.0% C: 0.0%
REGN | $896.27 0.26% 0.25% 500K |

Health Technology

| -6.07% | O: -0.14% H: 0.32% C: -0.57%
dupixent first japan urticaria world

---

Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)
Published: 2024-02-16 (Crawled : 06:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K |

Health Technology

| 0.42% | O: 1.66% H: 0.0% C: -1.59%
SNY | News | $46.32 2.05% 2.01% 3.3M |

Health Technology

| -0.45% | O: -0.6% H: 0.0% C: 0.0%
REGN | $896.27 0.26% 0.25% 500K |

Health Technology

| -6.07% | O: -0.14% H: 0.32% C: -0.57%
dupixent first japan urticaria world

---

Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
Published: 2024-02-02 (Crawled : 12:00) - globenewswire.com
TSVT | $4.52 -2.59% -2.65% 610K |

| -12.91% | O: -1.16% H: 9.94% C: 2.34%
SNY | News | $46.32 2.05% 2.01% 3.3M |

Health Technology

| -4.46% | O: -0.93% H: 0.0% C: 0.0%
REGN | $896.27 0.26% 0.25% 500K |

Health Technology

| -6.36% | O: 1.4% H: 0.28% C: -2.68%
ALNY | $144.315 -0.58% -0.59% 700K |

Health Technology

| -17.44% | O: -1.23% H: 1.0% C: 0.17%
year financial results

---

Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma
Published: 2024-02-02 (Crawled : 11:00) - globenewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M |

Health Technology

| -4.46% | O: -0.93% H: 0.0% C: 0.0%
REGN | $896.27 0.26% 0.25% 500K |

Health Technology

| -6.36% | O: 1.4% H: 0.28% C: -2.68%
treatment ema

---

Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs
Published: 2024-01-30 (Crawled : 12:00) - globenewswire.com
TSVT | $4.52 -2.59% -2.65% 610K |

| 29.51% | O: 11.17% H: 12.63% C: 3.35%
SNY | News | $46.32 2.05% 2.01% 3.3M |

Health Technology

| -7.79% | O: 0.12% H: 0.0% C: 0.0%
REGN | $896.27 0.26% 0.25% 500K |

Health Technology

| -6.17% | O: 0.02% H: 0.44% C: 0.39%
cell acquisition preclinical

---

Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
Published: 2024-01-25 (Crawled : 20:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K |

Health Technology

| -6.6% | O: 1.8% H: 0.0% C: -1.82%
SNY | News | $46.32 2.05% 2.01% 3.3M |

Health Technology

| -7.21% | O: 0.5% H: 0.0% C: 0.0%
REGN | $896.27 0.26% 0.25% 500K |

Health Technology

| -5.49% | O: 0.33% H: 0.65% C: -1.26%
dupixent fda first children approved year treatment

---

Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)
Published: 2024-01-25 (Crawled : 20:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K |

Health Technology

| -6.6% | O: 1.8% H: 0.0% C: -1.82%
SNY | News | $46.32 2.05% 2.01% 3.3M |

Health Technology

| -7.21% | O: 0.5% H: 0.0% C: 0.0%
REGN | $896.27 0.26% 0.25% 500K |

Health Technology

| -5.49% | O: 0.33% H: 0.65% C: -1.26%
dupixent fda first children approved year treatment

---

Dupixent® (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot Involvement
Published: 2024-01-16 (Crawled : 12:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K |

Health Technology

| -12.55% | O: -2.03% H: 0.05% C: 0.05%
SNY | News | $46.32 2.05% 2.01% 3.3M |

Health Technology

| -11.59% | O: -1.34% H: 0.0% C: 0.0%
REGN | $896.27 0.26% 0.25% 500K |

Health Technology

| -3.9% | O: -0.21% H: 0.67% C: 0.66%
dupixent label dermatitis

---

Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries
Published: 2024-01-08 (Crawled : 12:30) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K |

Health Technology

| -8.67% | O: 2.07% H: 0.48% C: 0.48%
SNY | News | $46.32 2.05% 2.01% 3.3M |

Health Technology

| -9.11% | O: 1.16% H: 0.0% C: 0.0%
REGN | $896.27 0.26% 0.25% 500K |

Health Technology

| -1.79% | O: -2.54% H: 1.53% C: 1.45%
libtayo pharma pharmaceuticals agreement

---

Biologics Global Market Forecast Report 2024-2034 - Challenges Posed by Patent Expiration for Biologics
Published: 2023-12-22 (Crawled : 17:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K |

Health Technology

| -3.25% | O: 3.66% H: 0.0% C: -0.12%
AZNCF | News | $138.24 -4.19% 800 |

Health Technology

| 4.37% | O: 3.33% H: 0.0% C: -2.93%
NVO | News | $122.71 -0.03% 0.17% 5M |

Health Technology

| 18.58% | O: -0.31% H: 0.39% C: -0.44%
JNJ | News | $147.91 1.49% -0.03% 9.6M |

Health Technology

| -3.65% | O: 1.09% H: 0.0% C: 0.0%
LLY | News | $726.31 -2.63% -0.04% 3.5M |

Health Technology

| 26.98% | O: 0.18% H: 0.5% C: -0.46%
BMY | $48.93 1.3% 0.0% 10M |

Health Technology

| -4.55% | O: -0.78% H: 5.15% C: 2.81%
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| 9.06% | O: 0.58% H: 0.0% C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M |

Health Technology

| -4.99% | O: 1.03% H: 0.0% C: 0.0%
REGN | $896.27 0.26% 0.25% 500K |

Health Technology

| 6.53% | O: 0.52% H: 0.58% C: 0.05%
GILD | $66.77 0.92% 0.91% 11M |

Health Technology

| -15.42% | O: 0.34% H: 1.02% C: 0.59%
BIIB | $194.39 2.03% 1.99% 1.6M |

Health Technology

| -23.43% | O: 0.57% H: 1.36% C: 1.04%
AZN | News | $68.56 0.29% 0.29% 4.7M |

Health Technology

| 3.39% | O: 1.06% H: 0.18% C: -1.06%
AMGN | $269.03 2.39% 2.33% 3.4M |

Health Technology

| -3.72% | O: 0.24% H: 2.03% C: 1.49%
patent report global market

---

Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes
Published: 2023-12-11 (Crawled : 01:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K |

Health Technology

| -0.54% | O: 0.5% H: 1.67% C: 0.1%
SNY | News | $46.32 2.05% 2.01% 3.3M |

Health Technology

| 0.19% | O: 2.15% H: 0.0% C: 0.0%
REGN | $896.27 0.26% 0.25% 500K |

Health Technology

| 6.75% | O: -0.2% H: 1.35% C: 1.19%

---

Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes
Published: 2023-12-10 (Crawled : 20:20) - globenewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M |

Health Technology

| Email alert Add to watchlist
SNYNF | News | $92.7 -2.18% 600K |

Health Technology

| Email alert Add to watchlist
REGN | $896.27 0.26% 0.25% 500K |

Health Technology

| Email alert Add to watchlist
trial potential

---

Gainers vs Losers

67%

33%

Top 10 Gainers

AGBA | News | $1.26 215.0% 68.25% 130M |

Finance

EGOX | $0.0515 43.06% 30.1% 330M |

OLB 4 | $0.33 -14.95% 25.53% 840K |

Technology Services

NVFY | $2.77 31.28% 23.83% 33M |

Consumer Durables

ZCMD | $1.87 28.97% 22.46% 31M |

Commercial Services

RCON | $0.1112 13.01% 21.28% 1.7M |

Distribution Services

INSG | $3.03 25.21% 20.13% 330K |

Electronic Technology

GCTK | $0.8191 22.25% 18.2% 190K |

Manufacturing

WLGS | $0.59 18.0% 17.9% 2.3M |

ASNS | $0.828 21.75% 17.86% 18K |

---

Your saved searches

---